Heterocyclic indazole derivatives

US8334309B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Markus Klein · Weiterstadt, DE
• Norbert Beier · Reinheim, DE

Key dates

• Filing date: Apr 18, 2008
• Grant date: Dec 18, 2012
• Expiry date: Jan 31, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.